Zoetis Inc. (ZTS) Now Covered by Analysts at Bank of America Corp.
A number of other research firms have also issued reports on ZTS. Jefferies Group restated a buy rating and set a $60.00 price target on shares of Zoetis in a report on Tuesday, August 23rd. Guggenheim reiterated a positive rating and issued a $60.00 price objective on shares of Zoetis in a research note on Monday, August 22nd. Citigroup Inc. lowered shares of Zoetis from a buy rating to a neutral rating and upped their price objective for the company from $46.00 to $50.00 in a research note on Friday, June 10th. They noted that the move was a valuation call. Barclays PLC upped their price objective on shares of Zoetis from $45.00 to $49.00 and gave the company an equal weight rating in a research note on Thursday, August 4th. Finally, Credit Suisse Group AG reiterated a focus list rating and issued a $60.00 price objective on shares of Zoetis in a research note on Wednesday, September 7th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $55.27.
Shares of Zoetis (NYSE:ZTS) opened at 51.02 on Thursday. Zoetis has a 1-year low of $38.26 and a 1-year high of $52.64. The company’s 50-day moving average is $51.27 and its 200 day moving average is $48.26. The stock has a market cap of $25.26 billion, a P/E ratio of 39.74 and a beta of 1.01.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.05. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the business earned $0.43 earnings per share. The firm’s revenue was up 2.8% compared to the same quarter last year. Equities research analysts anticipate that Zoetis will post $1.90 EPS for the current year.
In related news, insider Andrew Fenton sold 13,870 shares of the stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $51.25, for a total transaction of $710,837.50. Following the completion of the sale, the insider now owns 17,719 shares in the company, valued at approximately $908,098.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael B. Mccallister bought 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The shares were purchased at an average price of $51.34 per share, with a total value of $102,680.00. The disclosure for this purchase can be found here. Corporate insiders own 0.05% of the company’s stock.
Several large investors have recently made changes to their positions in the company. NEXT Financial Group Inc boosted its stake in shares of Zoetis by 9.5% in the second quarter. NEXT Financial Group Inc now owns 2,136 shares of the company’s stock worth $101,000 after buying an additional 186 shares during the period. Kelly Lawrence W & Associates Inc. CA raised its stake in shares of Zoetis by 113.4% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 2,446 shares of the company’s stock worth $116,000 after buying an additional 1,300 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new stake in shares of Zoetis during the first quarter worth approximately $118,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Zoetis by 22.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,566 shares of the company’s stock worth $121,000 after buying an additional 476 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its stake in shares of Zoetis by 4.4% in the second quarter. Glenmede Trust Co. NA now owns 2,950 shares of the company’s stock worth $139,000 after buying an additional 124 shares in the last quarter. Institutional investors and hedge funds own 93.12% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.